Since one of the primary pathophysiologies of obesity-related hypertension is through activation of the RAAS system, ACE inhibitors or angiotensin receptor blockers (ARBs) may be appropriate as an initial agent for pharmacologic therapy for hypertension in children. The gene discussed is ACE; the disease is obesity due to melanocortin 4 receptor deficiency.